{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:57:35Z","timestamp":1789952255432,"version":"4.0.1"},"reference-count":0,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Purif"],"published-print":{"date-parts":[[2020]]},"abstract":"<b><i>Introduction:<\/i><\/b> Primary focal and segmental glomerulosclerosis (FSGS) frequently reoccurs on kidney transplants and may lead to premature allograft loss. There are no guidelines for treating FSGS recurrence on allografts; treatment is based on apheresis (plasma exchange plasmapheresis [PP], semi-specific immunoadsorption [IA] with reusable columns) plus rituximab. <b><i>Objective:<\/i><\/b> We aimed to assess the efficacy of IA to treat recurrent FSGS. <b><i>Methods:<\/i><\/b> We report on 7 patients with recurrent FSGS on kidney allograft (proteinuria \u22653 g\/g of urinary creatinine or \u22653 g\/day); they all received IA. Our primary objective was to reduce proteinuria by &#x3e;50%. Patients\u2019 mean age was 45 \u00b1 10 years. Postoperative immunosuppression relied on steroids, mycophenolate mofetil, tacrolimus, with an induction therapy of basiliximab or antithymocyte globulins. Prophylaxis to prevent FSGS recurrence was either rituximab alone (<i>n<\/i> = 3), rituximab plus either PP\u00a0or IA (<i>n<\/i> = 3), or no treatment (<i>n<\/i> = 1). Mean follow-up was 20 \u00b1 13 months. There was a median of 72 (14\u2013101) IA sessions per patient, that is, a mean of 14 \u00b1 1 sessions per IA column. <b><i>Results:<\/i><\/b> At 12 months after starting IA, all patients had partial (<i>n<\/i> = 6) or complete (<i>n<\/i> = 1) remission, and allograft survival was 100%. The mean reduction in proteinuria within an IA session was 45 \u00b1 15%. At last follow-up, 2 patients are in remission without IA, 3 patients are in partial remission that is IA dependent, and 2 patients lost their allograft due to FSGS recurrence. The most frequent adverse event was cytomegalovirus reactivation (<i>n<\/i> = 13), which subsided after valganciclovir therapy. <b><i>Conclusions:<\/i><\/b> We show that recurrence of FSGS can be controlled long term with IA plus rituximab. However, some patients remained dependent on IA.<\/jats:p>","DOI":"10.1159\/000504244","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T22:00:37Z","timestamp":1578434437000},"page":"322-333","source":"Crossref","is-referenced-by-count":12,"title":["Immunoadsorption for Recurrent Primary Focal Segmental Glomerulosclerosis on Kidney Allografts: A Single-Center Experience and Literature Review"],"prefix":"10.1159","volume":"49","author":[{"given":"Hamza","family":"Naciri\u00a0Bennani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juste\u00a0Y\u00e9r\u00e9mand\u00e9","family":"Bonzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Terrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Imerzoukene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Bugnazet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Janbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Malvezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2020,1,7]]},"container-title":["Blood Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/504244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:08:37Z","timestamp":1745424517000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000504244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,5,4]]},"published-print":{"date-parts":[[2020,5,5]]}},"URL":"https:\/\/doi.org\/10.1159\/000504244","archive":["Portico"],"relation":{},"ISSN":["0253-5068","1421-9735"],"issn-type":[{"value":"0253-5068","type":"print"},{"value":"1421-9735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}